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Abstract
Purpose of Review—Acute and early HIV (AHI) is a pivotal time during HIV infection, yet 
there remain major shortfalls in diagnosis, linkage to care, and antiretroviral therapy (ART) 
initiation during AHI. We introduce an AHI-specific cascade, review recent evidence pertaining to 
the unique challenges of AHI, and discuss strategies for improving individual and public health 
outcomes.
Recent Findings—Presentation during AHI is common. Expanding use of 4th generation testing 
and pooled nucleic acid amplification testing (NAT) has led to improved AHI detection in 
resource-wealthy settings. Technologies capable of AHI diagnosis are rare in resource-limited 
settings; further development of point-of-care devices and utilization of targeted screening is 
needed. Rapid ART initiation during AHI limits reservoir seeding, preserves immunity, and 
prevents transmission. Reporting of AHI cascade outcomes is limited, but new evidence suggests 
that impressive rates of diagnosis, linkage to care, rapid ART initiation, and viral suppression can 
be achieved.
Summary—With advancements in AHI diagnostics and strong evidence for the therapeutic and 
prevention benefits of ART initiated during AHI, improving AHI cascade outcomes is both crucial 
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and feasible. HIV guidelines should recommend diagnostic algorithms capable of detecting AHI 
and prescribe rapid, universal ART initiation during AHI.
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Introduction
Acute HIV is a very brief but critical phase of HIV infection. Historically, acute HIV 
infection has been defined as lasting only until the emergence of HIV-specific antibodies 
(1), since lack of antibodies in the presence of viral RNA was used as an operational 
definition of the stage of disease. However, as antibody tests have become ever more 
sensitive and many patients have been followed from infection onward (2), it is wiser to 
consider acute and early HIV infection as a package (sometimes referred to as “primary 
infection”), since clearly the important events that transpire after infection extend for a 
longer time than required for antibodies to form (3). The exact time at which acute and early 
infection should be considered as “established” infection has not been resolved. However, 
the transmission risk associated with acute and early infection lasts at least 4 months (4).
Acute HIV infection and early HIV infection (heretofore referred to as AHI) are associated 
with extremely high viral loads, seeding of viral reservoirs and a disproportionate 
contribution to onward HIV transmission. Failure to diagnose and treat persons with AHI 
has significant individual and public health implications. Responding to these consequences, 
revised US HIV management guidelines now include HIV screening algorithms to detect 
AHI, and recommend antiretroviral therapy (ART) regardless of CD4+ T cell counts in 
persons with AHI (5). The updated International AIDS Society guidelines also recommend 
universal ART, and the most recent European AIDS Clinical Society Guidelines advocate 
consideration and discussion of ART initiation with the patient with AHI (6, 7). However, 
prominent international guidelines, such as those from the World Health Organization 
(WHO), have not yet defined a diagnostic strategy nor made any specific recommendation 
regarding ART initiation for persons with AHI (8).
In this paper, we propose an AHI-specific cascade (Figure 1) and explore the critical 
concerns that could be targeted in guidelines. AHI has unique challenges. These include 
limited detection of AHI through HIV testing algorithms, delays in ART initiation that 
compromise the individual and public health benefits of ART, and limited knowledge 
regarding success rates of linkage to and retention in HIV care.
Diagnosis of acute HIV infection
Perhaps no topic related to AHI attracts more attention and frustration than identification of 
this stage of infection. Identifying persons with AHI is complicated by the brevity of the 
phase, the non-specific symptoms associated with the HIV infection, and (at first) the 
absence of anti-HIV antibodies. Traditional point-of-care (POC) antibody tests cannot 
directly address this earliest phase of infection, so the diagnosis of AHI relies on the direct 
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detection of virus or viral antigen. (Parenthetically, discordance in particular POC rapid tests 
strongly suggests AHI, as discussed below).
Revised CDC guidelines outline diagnostic algorithms that detect AHI using a combination 
of 4th generation enzyme immunoassays (EIA) and nucleic acid testing (NAT) (9). Although 
WHO guidelines characterize 4th generation assays as “A1 assays” to be used where feasible 
for the detection of AHI, they provide no guidance for AHI screening or diagnosis (10). 
Expanded utilization of 4th generation assay can clearly help to diagnose persons earlier in 
the course of infection.
Due in part to their non-specific nature, clinical manifestations of acute infection are 
frequently misclassified (11, 12). In the United States, 55% of persons eventually diagnosed 
with AHI were missed on their first visit to the healthcare system (13). Patients in resource-
limited settings also commonly seek medical care for symptoms related to acute infection, 
but are instead often presumptively treated for malaria (11, 14). In one survey of Kenyan 
adults presenting to outpatient health centers with fever, the prevalence of AHI and malaria 
was identical at 1.7% (95% confidence interval (CI) 0.5%−4.2%) (15). Among febrile 
seronegative persons presenting to outpatient clinics Uganda, 2.8 % had AHI ; in 
Mozambique, AHI prevalence was 3.3% (95% CI 1.3%−6.7%) (16, 17). Risk score 
algorithms demonstrate the utility of AHI screening among seronegative patients presenting 
with certain symptoms and risk behavior histories (18, 19). Among higher risk patients, such 
an algorithm can lead to correct and efficient diagnosis of AHI, detecting 81.0% of patients 
with AHI by screening only 20.1% of the targeted patient population. These AHI detection 
algorithms deserve more attention.
Increased targeted screening for AHI may unearth substantial missed diagnoses. In resource-
limited settings, symptom-derived AHI risk scores help focus testing resources (12, 15, 18, 
20). Nonetheless, AHI is rarely considered among febrile adults in sub-Saharan Africa (21). 
WHO guidelines recommend HIV testing in the setting of >30 days of unexplained fever 
with a negative malaria test, but AHI is not mentioned as a potential cause of fever of 
shorter duration nor is AHI screening recommended for this patient population (22). 
Numerous technologies are available to narrow the window of diagnosis for persons with 
AHI; some have been incorporated into testing algorithms in resource-wealthy settings but 
none are routinely applied in resource-limited settings.
Fourth generation EIAs detect p24 antigen and antibody isotypes that emerge soon after 
infection. These assays serve as the backbone for HIV testing algorithms in the US (9). 
Identifying persons earlier in the course of infection compared to previous generations, 4th 
generation tests substantially improve AHI detection (23-26). In a Texas emergency 
department, 18/78 (23%) with confirmed positive results were acutely infected and would 
not have been diagnosed without 4th generation assays (27). However, these assays still miss 
high-risk populations presenting to care in the critical gap before emergence of p24 antigen 
(28). Additionally, the ARCHITECT HIV Ag/Ab (Abbott Diagnostics, Chicago IL), a 
widely used 4th generation assay, does not discriminate between the antigen and antibody 
targets of the assay and thus does not distinguish between acute and established HIV. The 
use of a modified signal-to-cutoff ratio in 4th generation EIAs may improve detection of 
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early HIV infection and improve discrimination between AHI and established infection (29). 
Ultimately though, nucleic acid amplification (NAT) testing is required to identify persons 
in this earlier window via detection of HIV RNA.
Use of pooled NAT (30) instead of or in conjunction with 4th generation assays identifies 
persons with AHI earlier than 4th generation alone (i.e. in the first two weeks of infection), 
and pooled specimen throughput and costs may be more suitable for AHI screening in 
resource-limited settings. In high- and low-prevalence settings, pooled NAT substantially 
increases the number of persons identified with AHI compared to standalone 4th generation 
testing (31, 32). Although pooling for AHI may be cost-effective (33), financial feasibility 
will depend on the underlying prevalence of AHI and specific pooling strategy. Ideal 
pooling strategies maximize batch size according to population risk profiles and HIV 
prevalence, with a tradeoff of increased complexity with larger pools. In a high-prevalence 
Thai cohort, addition of pooled NAT after 4th generation testing increased acute diagnosis 
by nearly 40% but also increased screening costs by 22% (31). Besides costs, laboratory-
based assays introduce logistical barriers to AHI screening, requiring venipuncture and 
patient follow-up
Effective POC tests for AHI would allow better widespread diagnostic capacity. The Alere 
Determine HIV-1/2 Ag/Ab lateral flow test was designed with this goal in mind. However, 
extensive field-based testing demonstrated that the product lacks the ability to reliably detect 
p24 antigen in blood, and is also compromised by false positive results (34-36).
Three recently introduced first-generation rapid NAT devices may be more promising: The 
Alere Q demonstrated excellent performance for early infant diagnosis in Mozambique (37); 
the SAMBA semiquantitaive assay, with a 1,000 copy/ml threshold, has demonstrated 
adequate performance on plasma (38); and the Liat HIV Quant cartridge-based viral load 
assay has shown promising results for POC viral load quantification (39). The ability of 
these POC technologies to detect HIV RNA suggests potential for an AHI screening assay. 
However, none of these tests have been field tested for detection of AHI, a critical 
requirement.
Antiretroviral therapy for acute and early HIV infection
During AHI, the virus integrates into host cell DNA, allowing the formation of a “latent 
reservoir”. ART initiated in AHI is to date the most effective strategy to limit HIV reservoir 
seeding (40-44) and reduce the number of infected cells (2, 45-48). Timing of ART 
initiation is critical as reservoir size is significantly smaller and decline in the number of 
infected cells is much faster in those who initiated ART within the first 2 weeks (prior to 
HIV IgM formation) vs. later (2). Cell-associated HIV DNA levels as low as those observed 
in elite controllers and post-treatment controllers can be achieved through very early 
treatment (42, 45, 49-51). In contrast, once individuals enter the chronic HIV infection 
phase, despite fully suppressive ART, they maintain a large reservoir size in blood and 
tissue that decays little over time (52, 53), leading to a rapid recrudescence of plasma 
viremia when ART is interrupted (54).
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Cell-associated HIV DNA levels may also predict subsequent ability to control viremia 
following treatment interruption (55, 56). AHI individuals who were randomized to 
immediate vs. deferred ART displayed significantly longer time to viral rebound and lower 
viral set point when ART was discontinued (49, 57-60). In addition, the actual decrease in 
time of exposure to ART by deferring treatment of patients with AHI is small, since most 
patients followed prospectively required treatment by traditional guidelines within a few 
years (57, 58).
CD4+ T cells depletion, immune exhaustion and immune activation occur early in HIV 
infection, and chances for a full recovery are reduced when ART is delayed (46, 50, 61-63). 
Viral escape from host immunologic response increases when HIV is left untreated leading 
to an alteration in the “viro-immunological” landscape that could impact natural control of 
the virus and efficacy of future immunotherapeutic interventions (64-66).
A related issue is the attempt to modify the course of infection with alternative, more 
aggressive treatment regimens. Several randomized studies comparing standard ART vs. 
regimens intensified with integrase and entry inhibitors showed plasma HIV RNA to decline 
more rapidly in the intensified arm; but all regimens were similarly effective in lowering 
cell-associated DNA and RNA and markers of immune activation as well as raising CD4+ T 
cell counts (49-51). Other non-randomized studies showed minimal to no benefit in 
intensifying standard ART regimens (67, 68). However, the more rapid viral load decline in 
blood and genital secretions with integrase inhibitor-based regimens may prove beneficial in 
reducing transmission risk during AHI (69).
Leveraging the acute HIV cascade for prevention
The potential to stop transmission from people with AHI is of great public health 
importance. Several lines of evidence suggest that HIV transmission is greatly amplified 
during AHI infection (4). The HIV founder virus(es) causing infection are particularly 
contagious (70) and the viral loads in AHI are exceptionally high (71). A series of modeling 
exercises suggest that patients with AHI fuel the epidemic (72) and phylogenetic analysis 
from Montreal (73), Switzerland (74), Amsterdam(75, 76) and San Francisco (77),all 
demonstrate exceptional contribution of AHI to spread of HIV in MSM. Studies from San 
Diego (78) and Malawi (3, 4) suggest that intervention in the first 4 months can reduce HIV 
spread.
A key barrier to intervention in AHI is the belief that action geared toward public health is 
infeasible. However, North Carolina’s Screening and Tracing Active Transmission Program 
has since 2002 successfully carried out statewide AHI screening and linkage to care, with 30 
day linkage and ART initiation rates of 80% and 61% (79, 80). An AHI study in New York 
City reports similar rates between patients newly diagnosed with AHI and established HIV 
of linkage within 3 months (92% vs 91%) retention at 12 months (86% vs 83%, p= 0.78) and 
suppression (65% vs 60%) (81). Additionally, a recent study reports 111/112 participants 
diagnosed with AHI at a Thai clinic were initiated on ART at their first care visit, a median 
of 19 days from the estimated date of their exposure to HIV, with excellent subsequent 
retention and viral suppression outcomes (31). Other studies involving rapid linkage and 
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ART initiation are currently in process (MP3, SEARCH, rapIT, Brigham/GHESKIO, 
Engage4Health, all clinicaltrials.gov).
The prevention benefits of diagnosis and care linkage during AHI extend beyond the 
opportunity to initiate early ART. Diagnosis during AHI coupled with risk reduction 
education or counseling has been associated with rapid reduction in self-reported 
transmission risk behaviors (82), and mathematical modeling suggests diagnosis during AHI 
and associated behavior change could have a significant impact on the UK MSM epidemic 
even in the absence of ART initiation (83).
The acute HIV cascade in practice
The concept of the HIV cascade has helped synchronize terminology and spur publication of 
large amounts of data on population-level HIV outcomes. However, information regarding 
AHI care outcomes outside of a research context remains scarce: public health surveillance 
data has traditionally not distinguished between AHI and established HIV diagnoses. 
However, when surveillance includes attempts to find infected people who are antibody 
negative, screening yield increases between 2-10% (30, 84-91). Yield varies according to 
diagnostic assays, risk profile of population (i.e. public health vs STI clinic), and underlying 
HIV prevalence. AHI screening yield is especially high among urban MSM in the US (84, 
88, 89).
In 2008 New York City implemented citywide AHI surveillance and procedures for 
streamlined entry to HIV care for AHI patients. Thus far, published cascade data outcomes 
are limited but demonstrate 77% of the 62 city residents diagnosed with AHI were linked to 
care within 3 months (92). Another series of one-year cascade outcomes in a U.S. 
community health clinic cohort of 93 patients diagnosed with AHI reports 87% retained in 
care, 62% initiated on ART, and 46% virally suppressed (93). The proportions were all 
slightly higher for AHI patients compared to the clinics’ patients newly diagnosed with 
established HIV.
Addressing the limited surveillance data collection on AHI outcomes, the CDC published 
new case definitions in 2014 creating an HIV stage 0, defined as a sequence of concurrent or 
sequential discordant test results indicative of AHI (94). This development promises to lead 
to a dramatically improved understanding of the state of the AHI cascade in the U.S.
Conclusion
The personal and public health benefits of treatment of AHI are now well established. 
Indeed, as the world moves toward a universal “test and treat” strategy it would seem very 
unwise to purposefully leave people with AHI untreated. A large series of randomized 
controlled trials (95-98) have all demonstrated an advantage to earlier ART. The Strategic 
Timing of AntiRetroviral Treatment (START) study was stopped by the NIH DSMB 
because of large differences in outcomes with early treatment started at CD4 counts >500 
cells/mm3. The cascade outlined in this report highlights the challenges unique to AHI: the 
differential diagnostic capacity according to resource setting, the highly time-sensitive 
nature of therapy initiation, and the opportunity to prevent transmission during a highly 
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infectious period. There are two critical levers through which modification of guidelines 
could improve AHI cascade outcomes: guidelines should incorporate diagnostic algorithms 
that include technologies capable of AHI detection, and, once diagnosed, guidelines must 
emphasize expedited linkage to care and ART initiation regardless of CD4+ T cell count. 
Maximal treatment benefits are gained through prompt ART initiation within days of 
diagnosis. This window is especially critical window for persons with AHI, and this 
opportunity will be missed if mechanisms to prioritize and urgently start ART in acutely-
infected individuals are not in place. Same-day ART has been successfully implemented in 
low and middle income countries (31, 99). There are substantial financial, technical, and 
logistical barriers involved in AHI diagnosis, linkage, and treatment; but revision of 
international guidelines is essential in order to begin to address these obstacles (Table 1).
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• Diagnosis of AHI is frequently missed despite many patients presenting to care 
during this critical phase of infection.
• Use of 4th generation EIA with pooled NAT substantially improves AHI case 
finding, and although these laboratory-based diagnostic tools have been 
incorporated into testing algorithms in the USA and Europe, the technologies 
are rarely available in resource-limited settings
• Immediate initiation of ART during AHI is critical to limit reservoir seeding, 
preserve immunologic function, and reduce transmission events during this 
highly-infectious period.
• Revisions to prominent international guidelines should define a diagnostic 
strategy and make specific recommendations regarding ART initiation for 
persons with AHI
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Figure 1. Acute HIV Infection Cascade
There remains little data to populate the acute HIV (AHI) cascade elements. Our proposed 
cascade highlights not only missed opportunities for diagnosis during this critical phase of 
infection, but also emphasizes opportunities to improve HIV outcomes through guideline 
modification that recognizes the importance of AHI diagnosis and immediate linkage to care 
with initiation of antiretroviral therapy.
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Table 1
Proposed AHI Guideline Modifications
Diagnosis Treatment
Recommendation: • Testing algorithms that effectively identify AHI should be 
used
○ Algorithms using 4th gen IA and pooled NAT should be 
used to diagnose AHI in EIA negative individuals
• In resource-constrained settings, risk score algorithms should 
be used to target screening to persons at highest risk for AHI.
• AHI screening should be included in clinical evaluations in 
settings whenever symptoms of acute retroviral syndrome are 
present, or when nonspecific symptoms such as fever are 
present in high HIV incidence groups.
• ART should be initiated 
regardless of CD4+ count and 
continued for life in persons 
diagnosed with AHI
• Linkage to care and ART 
initiation should occur as rapidly 
as possible in AHI, with a 
maximum window of 3 months 
from diagnosis.
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